Effectiveness of high-dose riboflavin in migraine prophylaxis: A randomized controlled trial

Neurology

Volumn 50, Issue 2, 1998, Pages 466-470

  Schoenen, J ^a,c   Jacquy, J ^b   Lenaerts, M ^d  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b FREE UNIVERSITY OF BRUSSELS   (Belgium)

^c Centre Hospitalier Regional de La Citadelle   (Belgium)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RIBOFLAVIN;

ADULT; ARTICLE; BELGIUM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LUXEMBOURG; MALE; MIGRAINE; ORAL DRUG ADMINISTRATION; POLYURIA; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL;

EID: 0031909628     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.2.466     Document Type: Article

References (25)

1. 31phosphorus NMR spectroscopy. Neurology 1989;39:538-541.
2. Montagna P, Sacquegna T, Cortelli P, Lugaresi E. Migraine as a defect of brain oxidative metabolism: a hypothesis. J Neurol 1989;236:124-125.
3. 31P magnetic resonance spectroscopy in patients affected by migraine with aura. Neurology 1992;42:1209-1214.
4. 31P-Magnetic resonance spectroscopy in migraine without aura. Neurology 1994; 44:666-668.
5. Sangiorgi S, Mochi M, Riva R, et al. Abnormal platelet mitochrondrial function in patients affected by migraine with and without aura. Cephalalgia 1994;14:21-23.
6. 1H-magnetic resonance spectroscopy in migraine during the interictal period. Neurology 1996;47:1093-1095.
7. Montagna P, Gallassi R, Medori R, et al. MELAS syndrome: characteristic migrainous and epileptic features and maternal transmission. Neurology 1988;38:751-754.
8. Goto Y, Horai S, Matsuoka T, Koga Y, Nihei K, Kobayashi M, Nonaka I. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): a correlative study of the clinical features and mitochondrial DNA mutation. Neurology 1992;42:545-550.
9. Arts WFM, Scholte HR, Boggard JM, Kerrebijn KF, Luyt-Houwen IEM. NADH-CoQ reductase deficient myopathy: successful treatment with riboflavin. Lancet 1983;2:581-582.
10. 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin. Neurology 1992;42:2147-2152.
11. Antozzi C, Garavaglia B, Mora M, et al. Late-onset riboflavin-responsive myopathy with combined multiple acyl coenzyme. A dehydrogenase and respiratory chain deficiency. Neurology 1994;44:2153-2158.
12. Scholte HR, Busch HF, Bakker HD, Bogaard JM, Luyt-Houwen IE, Kuyt LP. Riboflavin-responsive complex I deficiency. Biochim Biophys Acta 1995;1271:75-83. :
13. Schoenen J, Lenaerts M, Bastings E. High-dose riboflavin as a prophylactic treatment of migraine: results of an open pilot study. Cephalalgia 1994;14:328-329.
14. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(suppl 7):1-96.
15. International Headache Society Committee on Clinical Trials in Migraine. Guidelines for controlled trials of drugs in migraine. First edition. Cephalalgia 1991;11:1-12.
16. McQuay H, Carroll D, Jadad AR, Wiffen P, Moore A. Anticonvulsant drugs for management of pain: a systematic review. Br Med J 1995;311:1047-1052.
17. Armitage P, Berry G. Statistical methods in medical research, 3rd ed. Oxford: Blackwell Scientific Publications, 1994.
18. Andersson KE, Vinge E. β-Adrenoceptor blockers and calcium antagonists in the prophylaxis and treatment of migraine. Drugs 1990;39:355-373.
19. Toda N, Tfelt-Hansen P. Calcium Antagonists. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The headache. New York: Raven Press, 1993.
20. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology 1994;44:647-651.
21. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol 1995;52:2481-2486.
22. Peikert A, Wilimzig C, Köhne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996;16:257-263.
23. Diener HC, Föh M, Iaccarino C, et al. Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol. Cephalalgia 1996;16:441-447.
24. Klopstock T, May A, Seibel P, Papagiannuli E, Diener HC, Reichmann H. Mitochondrial DNA in migraine with aura. Neurology 1996;46:1735-1738.
25. Levy G, Mosovich LL, Allen JE, Yaffe SJ. Biliary excretion of riboflavin in man. J Pharm Sci 1972;61:143-144.